BioSpace News Archive

Healthtech company Geneial announces a multimillion dollar, non-dilutive award from the National Human Genome Research Institute to fund the development of their secure, decentralized platform.

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced today that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance.

Liquid biopsy cancer testing is one of the most transformational innovations in healthcare for the next decade, directly unlocking better outcomes for patients

AlzeCure Pharma AB announced that the company’s presentation from the pain conference IASP 2022 is now available in its entirety on the company’s website.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced plans to release its financial results for the third quarter of 2022 on November 3, 2022 after the close of the financial markets.

Revolution Medicines, Inc. today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-6291, an oral, selective, covalent KRASG12C(ON) Inhibitor designed to treat patients with cancers driven by the KRASG12C mutation.

Precision BioSciences, Inc. today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 8:30 a.m. ET.

Marinus Pharmaceuticals, Inc. today announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, exercised its first contract option, valued at approximately $12.3 million.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal fourth quarter and fiscal year ended June 30, 2022.